In hard to treat rheumatoid arthritis (RA) patients, conjugation of siRNA against C5 complement’s component with C5a receptor 1 (C5aR1)-specific Ab showed 83% reduction in RA-related symptoms compared to only 19% when siRNA and Ab were delivered unconjugated [117]. This evidence concerns the gene C5 and rheumatoid arthritis.